Moderate-to-Severe Atopic Dermatitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Moderate-to-Severe Atopic Dermatitis Market Outlook

Thelansis’s “Moderate-to-Severe Atopic Dermatitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate-to-Severe Atopic Dermatitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate-to-Severe Atopic Dermatitis Overview

Atopic dermatitis (AD) is a chronic inflammatory skin condition that typically begins in early childhood, causing age-specific skin problems, dryness, and severe itching. This condition significantly impacts the quality of life and makes patients more prone to allergic diseases. Numerous studies have linked AD during infancy to the later development of asthma, allergic rhinitis, and food allergies. About 80% of AD patients experience one or both of these conditions. Additionally, 35% of children with AD have food allergies, and they are more likely to suffer from skin infections and keratoconjunctivitis compared to the general population. Common chronic comorbidities in children with AD include asthma, psychosocial disorders, visual impairment, limb anomalies, and developmental issues. These comorbidities are more prevalent in those with AD. This group's most frequent acute conditions are upper respiratory tract infections, otitis media, conjunctivitis, and pharyngitis.

• Thelansis indicates that globally, AD affects 15%–20% of children and 1%–3% of adults. The prevalence of AD is increasing worldwide and varies by geographic location, with higher rates in industrialized, high-income countries compared to agriculture-based, low-income regions.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2024-2034

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: